Emblaveo is an antibiotic used in adults to treat: - Complicated (difficult to treat) intra-abdominal (belly) infections; - Hospital-acquired pneumonia (an infection of the lungs that is caught during a hospital stay), including ventilator-associated pneumonia (pneumonia that develops in patients who use a machine called a ventilator to help them breathe); - Complicated infections of the urinary tract (parts of the body that collect and pass out urine), including pyelonephritis (kidney infection); - Infections due to certain types of bacteria called aerobic gram-negative bacteria when patients have limited treatment options. Emblaveo contains the active substances aztreonam and avibactam.
Therapeutic Indication
### Therapeutic indication Emblaveo is indicated for the treatment of the following infections in adult patients (see sections 4.4 and 5.1): • Complicated intra-abdominal infection (cIAI) • Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) • Complicated urinary tract infection (cUTI), including pyelonephritis Emblaveo is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options (see sections 4.2, 4.4, and 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Therapeutic Area (MeSH)
ATC Code
J01DF51
ATC Item
xj 01 df 51
Pharmacotherapeutic Group
Antibacterials for systemic use
Active Substance (Summary)
INN / Common Names
EMA Name
Emblaveo
Medicine Name
Emblaveo
Aliases
N/ANo risk management plan link.
